Optimizing T cell immune response to cancer using IL-1R1 and its ligands
Official title: Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer
Funded at Brigham and Women's Hospital · NIH-10931686 · Data updated 2026-11-12
This study is looking at how certain proteins in the immune system can help T cells fight cancer better, and it’s for anyone interested in new ways to improve cancer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $587,394 |
| NIH project number | 5R01CA279457-02 |
| Project ID | NIH-10931686 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancer who may benefit from improved immunotherapy options.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have a strong immune response may not receive benefits from this research.
What this research studies
This research investigates how the IL-1R1 receptor and its ligands can enhance the immune response of T cells against cancer. By examining the roles of IL-1α and IL-1β, the study aims to understand how blocking these molecules can improve T cell activation and modify the tumor microenvironment to favor anti-cancer immunity. The approach involves using mouse models to explore the complex interactions between these cytokines and T cells, with the goal of developing more effective cancer immunotherapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cancer by enhancing the body's immune response.
How similar studies have gone: Previous studies, such as the CANTOS trial, have shown promising results in blocking IL-1β and its association with reduced cancer incidence, indicating potential for success in similar approaches.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Kupper, Thomas S. — Brigham and Women's Hospital
- Study coordinator: Kupper, Thomas S.
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large study will test whether taking rosuvastatin every day for a year can lower the chance of dangerous blood clots in people with cancer, without raising the risk of bleeding.
-
Preterm infant body composition and early-life health after NICU stay
This grant studies how body composition in very preterm babies relates to later brain development and risk of obesity or diabetes, with findings meant to improve care from NICU through early childhood.
-
Rapid Emergency Skills for Prehospital Optimization and Delivery (RESPOND) for Guatemala
A lightweight, AI-enabled prehospital training and triage program helps volunteer firefighters in Guatemala deliver faster, better care to trauma patients.
-
Rapid Emergency Skills for Prehospital Optimization and Notification in Guatemala
A mobile, AI-powered training and triage program helps volunteer emergency responders in Guatemala provide faster, safer trauma care and notify hospitals more quickly.
-
Understanding antibiotic allergy to improve care for patients
Scientists are testing new ideas to understand why some people develop severe allergic reactions to antibiotics and how to prevent or treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.